Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of virtual reality intervention on hospitalized patients with acute pain after thoracoscopic surgery: a pilot randomized clinical trial.

International journal of surgery (London, England)·2025
Same author

Unravelling the prognostic and operative role of intratumoural microbiota in non-small cell lung cancer: Insights from 16S rRNA and RNA sequencing.

Clinical and translational medicine·2025
Same author

Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.

Journal of the National Comprehensive Cancer Network : JNCCN·2024
Same author

Lobe-specific analysis of perioperative chemotherapy for non-small cell lung cancer patients.

Cancer medicine·2023
Same author

Family with Sequence Similarity 72 (FAM72) - A prospective biomarker for poor prognosis in patients with oral squamous cell carcinoma.

Archives of oral biology·2023
Same author

Oral microbial changes and oral disease management before and after the treatment of hematological malignancies: a narrative review.

Clinical oral investigations·2023

Related Experiment Video

Updated: Jan 13, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.4K

Immune Checkpoint Therapy for Thymic Carcinoma.

Jinhui Li1, Fuling Mao1, Hongyu Liu2

  • 1Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China.

Cancers
|October 29, 2025
PubMed
Summary

Immune checkpoint inhibitors show promise for thymic carcinoma (TC), but efficacy is limited. Future strategies focus on combination therapies and novel targets to improve outcomes and reduce side effects.

Keywords:
immune checkpoints inhibitorsimmune-related adverse eventsprogrammed cell death protein 1programmed cell death protein ligand 1thymic carcinoma

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.5K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K

Related Experiment Videos

Last Updated: Jan 13, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.4K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.5K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K

Area of Science:

  • Oncology
  • Immunology

Background:

  • Thymic carcinoma (TC) is a rare, aggressive cancer of thymus epithelial cells.
  • TC exhibits distinct pathological, clinical, and immune features compared to other thymic tumors.

Purpose of the Study:

  • To review the efficacy and safety of immune checkpoint inhibitors (ICIs) in advanced thymic carcinoma.
  • To explore combination therapies, emerging targets, and future strategies for TC treatment.

Main Methods:

  • Literature review of studies on ICI monotherapy and combination approaches in TC.
  • Analysis of biomarkers, including PD-1/PD-L1 expression and CD8+ tumor-infiltrating lymphocytes (TILs).
  • Consideration of novel therapeutic targets like CD70, TIM-3, and B7-H4.

Main Results:

  • ICI targeting the PD-1/PD-L1 pathway shows potential in advanced TC, possibly due to PD-L1 overexpression and CD8+ TILs.
  • ICI monotherapy offers disease control for some patients but has limited overall efficacy and unique immune-related adverse events (irAEs).
  • The predictive value of biomarkers like PD-L1 expression requires consistent assessment criteria.

Conclusions:

  • Combination therapies (anti-angiogenic agents, chemotherapy, dual checkpoint blockade) are being investigated to enhance ICI efficacy.
  • Novel targets and biomarker-based patient selection are crucial for improving treatment durability and reducing toxicity in TC.
  • Tailored therapeutic strategies are essential for optimizing outcomes in advanced thymic carcinoma.